Zimmer Biomet Reports Mixed 2025 Results, Authorizes $1.5B Buyback Amid Tax Dispute & Operational Shifts

summarizeSummary

Zimmer Biomet reported a 7.2% increase in 2025 net sales to $8.23 billion, but net earnings and diluted EPS declined significantly, while authorizing a new $1.5 billion share repurchase program and disclosing a material IRS tax dispute.

check_boxKey Events

• Full-Year 2025 Financial Results

  Net sales increased 7.2% to $8.23 billion, but net earnings decreased to $705.1 million from $903.8 million in 2024, and diluted EPS fell to $3.55 from $4.43. The decline was driven by $170 million in inventory and instrument charges, acquisition costs, higher interest expense, and U.S. tariffs.

• 2026 Financial Outlook

  The company projects year-over-year net sales growth of 2.5% to 4.5% and an increase in operating profit for 2026. This growth is expected from market expansion, new product introductions, and restructuring savings, but will be partially offset by changes to go-to-market strategies, price declines, and higher net interest expense.

• New Share Repurchase Program Authorized

  The Board of Directors authorized a new $1.5 billion share repurchase program effective February 9, 2026, terminating the previous $2.0 billion program. In Q4 2025, the company repurchased $487.0 million of common stock under the prior program.

• Strategic Acquisitions in 2025

  Zimmer Biomet completed the acquisitions of Paragon 28 for $1.27 billion and Monogram Technologies Inc. for $377.5 million in 2025, expanding its portfolio in foot and ankle orthopedics and robotic technologies, respectively. These acquisitions included significant contingent consideration liabilities.

auto_awesomeAnalysis

Zimmer Biomet's 2025 annual report reveals a complex financial picture with strong sales growth offset by a significant decline in net earnings and diluted EPS. The company is actively pursuing strategic acquisitions and returning capital to shareholders through a new $1.5 billion share repurchase program. However, these positives are tempered by substantial inventory and acquisition-related costs, and a material ongoing dispute with the IRS that could result in significant tax liabilities. Investors should monitor the progress of the IRS dispute and the execution of the sales force transformation, as these carry notable financial and operational risks.